Researchers from the Liver Program at Smilow Cancer Hospital have recently published three new studies in Nature Reviews Gastroenterology & Hepatology, Hepatology, and Cancers. These studies focus on cholangiocarcinoma (CCA), the most common biliary tract malignancy, and ways to improve diagnosis and treatment options, as well as hepatocellular carcinoma (HCC), the most frequent primary liver cancer.
Despite advances in CCA awareness, knowledge, diagnosis, and therapies, patient prognosis has not improved substantially in the past decade. Involving investigators from around the globe, and published in Nature Reviews Gastroenterology & Hepatology, “Cholangiocarcinoma 2020: the next horizon in mechanisms and management” is an International Consensus paper. Luca Fabris, MD, PhD, Associate Professor Adjunct of Medicine (Digestive Diseases), Internal Medicine, and Mario Strazzabosco, MD, PhD, Professor of Medicine, Clinical Program Leader of the Liver Cancer Program, and Deputy Director of the Yale Liver Center, are authors on the paper and Yale is one of only two Centers in the US that participated. The second study, published in Hepatology, is titled “The Tumor Microenvironment in Cholangiocarcinoma Progression,” and the third study, “Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective?” was published in Cancers. Dr. Strazzabosco is an author on both papers.
These studies, done in collaboration with prestigious international centers, provide essential insight into rare cancers, where not much information is known.